Bayer announces Q3 core EPS of EUR 0.57, up from EUR 0.24 a year ago

Financial Performance: Bayer reported group sales of EUR 9.7B, a decrease from EUR 9.97B last year, with a net income loss of EUR 963M compared to a loss of EUR 4.2B the previous year.

CEO Insights: CEO Bill Anderson emphasized the resilience of the agricultural business and the Pharmaceuticals Division, while noting challenges in the Consumer Health sector, and expressed confidence in meeting the 2025 Group guidance.

Pharmaceuticals Pipeline: The company is set to launch Lynkuet, a hormone-free menopause treatment, in the US this month, showcasing progress in its Pharmaceuticals pipeline.

Crop Science Innovations: Bayer's Crop Science division launched the Plenexos insecticide in Latin America and is focused on executing its Five-Year Framework, aiming for innovative crop solutions and further reducing net financial debt.